Thalassemia

The thalassemias are inherited disorders in which one of the globin chains of hemoglobin is synthesized in reduced amount or not at all. The resulting imbalance between alpha- and beta-globin chains leads to ineffective erythropoiesis and hemolytic anemia. They are classified by the affected chain (alpha- or beta-thalassemia) and span a clinical spectrum from silent carrier states to transfusion-dependent disease.

Definition

Thalassemia is a group of inherited quantitative defects of hemoglobin in which mutations reduce or abolish the synthesis of an otherwise structurally normal alpha- or beta-globin chain, producing an imbalance of globin chains, ineffective erythropoiesis, and hemolytic anemia.

Scope

This topic covers the molecular basis of reduced globin synthesis, the distinction between alpha- and beta-thalassemia, the consequences of unbalanced chain accumulation, and the population genetics that explain the geographic distribution of these disorders. It is a reference entry and does not provide individualized clinical management.

Core questions

• How does reduced synthesis of one globin chain cause anemia through chain imbalance?
• What distinguishes alpha-thalassemia from beta-thalassemia in mechanism and clinical timing?
• How do genotype and co-inherited modifiers determine position on the clinical spectrum from carrier to transfusion-dependent disease?

Key concepts

• Quantitative globin-synthesis defect
• Alpha- versus beta-globin chain imbalance
• Ineffective erythropoiesis
• Microcytic, hypochromic anemia
• Transfusion dependence and iron overload
• Thalassemia trait (carrier state)
• Compound states (e.g., HbE/beta-thalassemia)

Mechanisms

Thalassemia arises from mutations that reduce or eliminate production of an otherwise normal globin chain. Because alpha- and beta-globin are normally made in balanced amounts, a deficit of one chain leaves the partner chain in relative excess. The unmatched chains precipitate within developing and circulating red cells, damaging membranes and causing premature destruction of erythroid precursors in the marrow (ineffective erythropoiesis) and of mature cells in the circulation (hemolysis). The net result is a microcytic, hypochromic anemia whose severity tracks the degree of chain imbalance. In beta-thalassemia the excess alpha chains are especially toxic, and severity ranges from the asymptomatic trait to severe, transfusion-requiring disease; in alpha-thalassemia the number of functional alpha genes lost determines whether the result is a silent carrier state, mild anemia, or, in the most severe form, a disorder evident before birth.

Clinical relevance

Thalassemias are a major cause of inherited microcytic anemia and a common consideration in the workup of anemia and in carrier screening programs. Recognizing the chain-imbalance mechanism helps explain why these disorders differ from iron deficiency despite a similar blood-count picture. This entry is for reference and education and is not a substitute for individualized diagnosis or treatment.

Epidemiology

Thalassemia alleles reach high frequency across the Mediterranean basin, the Middle East, the Indian subcontinent, and Southeast Asia, a distribution attributed to a carrier survival advantage against malaria. Williams and Weatherall describe the hemoglobinopathies, thalassemia among them, as a substantial and globally spreading health burden, with the disease now seen well beyond its historical regions through population movement.

History

Severe beta-thalassemia was first described clinically by Cooley and Lee in the 1920s as a form of childhood anemia, and the condition long carried the eponym Cooley's anemia. Mid-twentieth-century work, much of it associated with Weatherall and colleagues, established the thalassemias as quantitative defects of globin synthesis and elucidated the molecular lesions in the globin gene clusters. The recognition that their high frequency reflected malaria selection placed them, alongside the structural variants, within the population genetics of the hemoglobinopathies.

Key figures

• Thomas B. Cooley
• David Weatherall
• Renzo Galanello
• Eliezer Rachmilewitz
• Thomas N. Williams

Seminal works

• rund-2005
• galanello-2010
• williams-weatherall-2012

Frequently asked questions

What is the difference between alpha- and beta-thalassemia?

They differ in which globin chain is underproduced: alpha-thalassemia involves reduced alpha-globin synthesis and beta-thalassemia involves reduced beta-globin synthesis. Because beta-globin disorders depend on the fetal-to-adult hemoglobin switch, beta-thalassemia typically becomes apparent after the first months of life, whereas severe alpha-thalassemia can present before birth.

How does thalassemia differ from iron-deficiency anemia if both are microcytic?

Both produce small, pale red cells, but thalassemia results from an inherited imbalance in globin-chain synthesis rather than a shortage of iron. Iron stores are typically normal or increased in thalassemia, so it is not corrected by iron and is distinguished by hemoglobin analysis and family history.